The induced weight loss as well as the glycemic control achieved by GLP-1 RAs are parameters with significant roles in NASH development and progression but cannot account on their own for the beneficial effects observed in the performed clinical trials. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.